CRISPR Therapeutics AG (CRSP) Income Quarterly - Discounting Cash Flows
CRSP
CRISPR Therapeutics AG
CRSP (NASDAQ)
Period Ending: LTM
(Last Twelve Months)
2025 (Q4)
12-31
2025 (Q3)
09-30
2025 (Q2)
06-30
2025 (Q1)
03-31
2024 (Q4)
12-31
2024 (Q3)
09-30
2024 (Q2)
06-30
2024 (Q1)
03-31
2023 (Q4)
12-31
2023 (Q3)
09-30
2023 (Q2)
06-30
2023 (Q1)
03-31
2022 (Q4)
12-31
2022 (Q3)
09-30
2022 (Q2)
06-30
2022 (Q1)
03-31
2021 (Q4)
12-31
2021 (Q3)
09-30
2021 (Q2)
06-30
2021 (Q1)
03-31
2020 (Q4)
12-31
2020 (Q3)
09-30
2020 (Q2)
06-30
2020 (Q1)
03-31
2019 (Q4)
12-31
2019 (Q3)
09-30
2019 (Q2)
06-30
2019 (Q1)
03-31
2018 (Q4)
12-31
2018 (Q3)
09-30
2018 (Q2)
06-30
2018 (Q1)
03-31
2017 (Q4)
12-31
2017 (Q3)
09-30
2017 (Q2)
06-30
2017 (Q1)
03-31
2016 (Q4)
12-31
2016 (Q3)
09-30
2016 (Q2)
06-30
2016 (Q1)
03-31
2015 (Q4)
12-31
2015 (Q3)
09-30
2015 (Q2)
06-30
2015 (Q1)
03-31
Report Filing 2026-02-12 2026-02-12 2025-11-10 2025-08-04 2025-05-06 2025-02-11 2024-11-05
1234
Revenue 2.62 0.864 0.889 0 0.865 35 0
1234
Cost of Revenue 226.7 59.36 64.69 45.15 57.51 0 11.15
1234
Gross Profit -224.1 -58.5 -63.8 -45.15 -56.64 35 -11.15
1234
Operating Expenses 440.5 96.26 68.25 184.2 91.78 99.59 98.98
1234
Research & Development 375.4 77.86 58.9 166.1 72.48 82.16 82.16
1234
Selling, General and Administrative 73.54 18.4 16.93 18.92 19.3 18.12 17.42
1234
Other Operating Expenses -8.47 0 -7.58 -0.892 0 -0.691 -0.602
1234
Operating Income -664.6 -154.8 -132.1 -229.3 -148.4 -64.59 -110.1
1234
Net Non-Operating Interest 0 0 0 0 0 0 0
1234
Interest Income 0 0 0 0 0 0 0
1234
Interest Expense 0 0 0 0 0 0 0
1234
Equity & Other Income/(Expense) 86.61 24.77 26.24 22.07 13.54 27.98 25.06
1234
Income Before Tax -578 -130 -105.8 -207.3 -134.9 -36.61 -85.07
1234
Income Tax Expense 3.63 0.614 0.619 1.29 1.11 0.7 0.876
1234
Income Attributable to Non-Controlling Interest 0 0 0 0 0 0 0
1234
Net Income -581.6 -130.6 -106.4 -208.5 -136 -37.31 -85.94
1234
Depreciation and Amortization 19.48 5.66 4.43 4.65 4.74 4.84 4.74
1234
EBITDA -645.1 -149.1 -127.6 -224.7 -143.7 -59.75 -105.4
1234
Earnings Per Share (EPS) -6.52 -1.37 -1.17 -2.4 -1.58 -0.44 -1.01
1234
Diluted Earnings Per Share -6.52 -1.37 -1.17 -2.4 -1.58 -0.44 -1.01
1234
Weighted Average Shares Outstanding 89.93 89.93 91.31 87.07 85.94 85.46 85.23
1234
Diluted Weighted Average Shares Outstanding 89.93 89.93 91.31 87.07 85.94 85.46 85.23
1234
discounting cash flows home logo

Discounting Cash Flows

Are you finding our services helpful? Review us on trustpilot logo Trustpilot
Have a question? Contact us
Want to become our sponsor?
Check out our Affiliate Program